LifeMD (NASDAQ:LFMD) Stock Rating Reaffirmed by Cantor Fitzgerald

LifeMD (NASDAQ:LFMDGet Free Report)‘s stock had its “overweight” rating reissued by research analysts at Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga reports. They currently have a $7.00 target price on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 44.33% from the stock’s current price.

A number of other brokerages also recently issued reports on LFMD. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of LifeMD in a report on Friday, August 11th. B. Riley boosted their price objective on LifeMD from $3.50 to $7.00 in a research note on Monday, July 10th.

View Our Latest Report on LifeMD

LifeMD Stock Down 0.2 %

Shares of LFMD opened at $4.85 on Thursday. The stock has a 50 day moving average price of $4.18 and a 200 day moving average price of $2.87. The company has a market capitalization of $174.76 million, a price-to-earnings ratio of -4.66 and a beta of 1.69. LifeMD has a 52-week low of $1.14 and a 52-week high of $5.45.

LifeMD (NASDAQ:LFMDGet Free Report) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.14). The business had revenue of $35.95 million during the quarter, compared to analyst estimates of $35.29 million. LifeMD had a negative net margin of 23.30% and a negative return on equity of 7,255.81%. On average, equities analysts anticipate that LifeMD will post -0.65 EPS for the current fiscal year.

Insider Buying and Selling at LifeMD

In other news, Director Bertrand Velge acquired 32,072 shares of LifeMD stock in a transaction on Tuesday, August 29th. The stock was bought at an average price of $3.58 per share, for a total transaction of $114,817.76. Following the completion of the purchase, the director now owns 249,482 shares in the company, valued at $893,145.56. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 18.89% of the stock is owned by company insiders.

Institutional Investors Weigh In On LifeMD

Large investors have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in shares of LifeMD during the second quarter worth approximately $25,000. Squarepoint Ops LLC purchased a new stake in shares of LifeMD during the first quarter worth approximately $28,000. Renaissance Technologies LLC raised its stake in shares of LifeMD by 50.0% during the first quarter. Renaissance Technologies LLC now owns 16,500 shares of the company’s stock worth $28,000 after purchasing an additional 5,500 shares during the last quarter. CI Private Wealth LLC purchased a new stake in shares of LifeMD during the fourth quarter worth approximately $29,000. Finally, Virtu Financial LLC purchased a new position in LifeMD in the fourth quarter worth $62,000. Hedge funds and other institutional investors own 17.57% of the company’s stock.

LifeMD Company Profile

(Get Free Report)

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including urgent and primary care, men's and women's health, and dermatology, chronic care management, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and food and drug administration approved medical device for male and female hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and NavaMD, a female-oriented and tele-dermatology brand that offers virtual medical treatment from dermatologists and other providers.

Further Reading

Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with's FREE daily email newsletter.